Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 9/20 | 0.46 |
| ▸ | PNP | P00491 | 3/20 | 0.43 |
| ▸ | TK1 | P04183 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4621403 | 0.85 | XDH (0.50) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL986800 | 0.83 | XDH (0.60) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL15005119 | 0.82 | XDH (0.59) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL1825531 | 0.77 | XDH (0.51) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL79000 | 0.76 | XDH (0.51) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL1831279 | 0.76 | XDH (0.50) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL72147 | 0.73 | XDH (0.50) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL7513539 | 0.73 | XDH (0.51) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL1375443 | 0.73 | XDH (0.54) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL556881 | 0.72 | XDH (0.50) | XDHPNPTK1BLMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439351-B2 | 2′ or 3′ -deoxy and 2′, 3′-dideoxy-β-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents | THE UAB RESEARCH FOUNDATION (US) | 2008-10-21 | — | — | US | disclosed |
| US-20050101776-A1 | 2' or 3' -deoxy and 2' , 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents | GOSSELIN GILLES (FR) | 2005-05-12 | — | — | US | disclosed |
| US-20020120130-A1 | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents | GOSSELIN GILLES (FR) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101776-A1 | 2' or 3' -deoxy and 2' , 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents | DUT, DCTD, DERA | XDH 812/4885PNP 16/4885TK1 40/4885 |
| US-20020120130-A1 | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents | DUT, DCTD, TYMP | XDH 880/4885PNP 18/4885TK1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.